JDRF T1D Fund Investor

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Through partnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Invests into

Investors

Acquisitions Number: 23
Founded Date: 2016-12-01
Headquarters: Boston, Massachusetts, United States
Investors Number: 42
Technology: N/A
Employee Number: 11-50
Industry: Preventive Medicine
Estimated Revenue: $57 million
Number Of Exists: 8
Funding Status: N/A
Investor Type: Venture Capital
Investment Stage: Undisclosed
Register and Claim Ownership